Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZ) Cash & Equivalents (2021 - 2026)

Core Scientific has reported Cash & Equivalents over the past 6 years, most recently at $1.0 billion for Q1 2026.

  • Quarterly results put Cash & Equivalents at $1.0 billion for Q1 2026, up 44.02% from a year ago — trailing twelve months through Mar 2026 was $1.0 billion (up 44.02% YoY), and the annual figure for FY2025 was $311.4 million, down 62.76%.
  • Cash & Equivalents reached $1.0 billion in Q1 2026 per CORZ's latest filing, up from $311.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $1.0 billion in Q1 2026 and bottomed at $15.9 million in Q4 2022.
  • Median Cash & Equivalents over the past 5 years was $98.1 million (2024), compared with a mean of $282.4 million.
  • Peak annual rise in Cash & Equivalents hit 6186.29% in 2022, while the deepest fall reached 86.52% in 2022.
  • Over 5 years, Cash & Equivalents stood at $15.9 million in 2022, then skyrocketed by 217.36% to $50.4 million in 2023, then skyrocketed by 1558.83% to $836.2 million in 2024, then tumbled by 62.76% to $311.4 million in 2025, then skyrocketed by 222.81% to $1.0 billion in 2026.
  • Business Quant data shows Cash & Equivalents for CORZ at $1.0 billion in Q1 2026, $311.4 million in Q4 2025, and $453.4 million in Q3 2025.